Bevacizumab-induced serious side-effects: a review of the French pharmacovigilance database View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2012-07

AUTHORS

Solène Taugourdeau-Raymond, F. Rouby, A. Default, M.-J. Jean-Pastor, the French Network of the Pharmacovigilance Centers

ABSTRACT

PURPOSE: Bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor, is widely used in association with standard chemotherapy in metastatic cancer. Well tolerated, bevacizumab is sometimes associated with serious adverse drug reactions (ADRs). The objective of this study is to describe the profile of ADRs related to bevacizumab and reported to the French Pharmacovigilance system. METHOD: All serious cases of ADRs associated with bevacizumab recorded in the French Pharmacovigilance database up to November 31, 2010 were identified and analyzed, focusing on patient information, drug exposure, and characteristics of the ADRs. Categorical variables were compared using the chi-square test when appropriate. RESULTS: A total of 351 serious cases involving 626 ADRs were recorded in the database during the study interval. The most frequent ADRs reported involved the gastrointestinal system (21.9%). The most frequent ADRs included gastrointestinal perforation (4.8%), thromboembolic events (4.0%), pulmonary embolism (3.2%), hypertension (2.7%), gastrointestinal hemorrhage (2.7%), and cerebral hemorrhage or vascular accident (2.6%). The median duration of bevacizumab exposure was four cycles (range 1-30) when ADRs occurred. In 18 cases of death directly caused by ADRs, 50% occurred after only one cycle. In cases of disability, 40% of ADRs were neurologic: neuropathy, paralysis, and paresis. CONCLUSION: To the best of our knowledge, this is the first analysis of bevacizumab safety profile using data collected in a national pharmacovigilance database. Our study confirms the frequency and seriousness of gastrointestinal, thromboembolic, and hemorrhage events with bevacizumab use and provides a picture of the bevacizumab safety profile in daily medical practice, despite intrinsic limitations. More... »

PAGES

1103-1107

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00228-012-1232-7

DOI

http://dx.doi.org/10.1007/s00228-012-1232-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1004299839

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22349162


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adverse Drug Reaction Reporting Systems", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiogenesis Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bevacizumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child, Preschool", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Databases, Factual", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug-Related Side Effects and Adverse Reactions", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "France", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pharmacovigilance", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "H\u00f4pital Salvator", 
          "id": "https://www.grid.ac/institutes/grid.414441.0", 
          "name": [
            "H\u00f4pital Salvator, Assistance Publique des H\u00f4pitaux de Marseille (AP-HM), Centre R\u00e9gional de Pharmacovigilance, 249 Boulevard Sainte Marguerite, 13009, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Taugourdeau-Raymond", 
        "givenName": "Sol\u00e8ne", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H\u00f4pital Salvator", 
          "id": "https://www.grid.ac/institutes/grid.414441.0", 
          "name": [
            "H\u00f4pital Salvator, Assistance Publique des H\u00f4pitaux de Marseille (AP-HM), Centre R\u00e9gional de Pharmacovigilance, 249 Boulevard Sainte Marguerite, 13009, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rouby", 
        "givenName": "F.", 
        "id": "sg:person.01251754413.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01251754413.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H\u00f4pital Salvator", 
          "id": "https://www.grid.ac/institutes/grid.414441.0", 
          "name": [
            "H\u00f4pital Salvator, Assistance Publique des H\u00f4pitaux de Marseille (AP-HM), Centre R\u00e9gional de Pharmacovigilance, 249 Boulevard Sainte Marguerite, 13009, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Default", 
        "givenName": "A.", 
        "id": "sg:person.01244544521.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01244544521.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H\u00f4pital Salvator", 
          "id": "https://www.grid.ac/institutes/grid.414441.0", 
          "name": [
            "H\u00f4pital Salvator, Assistance Publique des H\u00f4pitaux de Marseille (AP-HM), Centre R\u00e9gional de Pharmacovigilance, 249 Boulevard Sainte Marguerite, 13009, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jean-Pastor", 
        "givenName": "M.-J.", 
        "id": "sg:person.01312657721.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01312657721.32"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "the French Network of the Pharmacovigilance Centers", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/j.clinthera.2006.11.015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015591784"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1359-6349(08)70290-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020222895"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(09)70112-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024981528"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(00)02799-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026617336"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.2008.656", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048505634"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6603813", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051627506", 
          "https://doi.org/10.1038/sj.bjc.6603813"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0049-3848(10)70014-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053698315"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.288.13.1588", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1054166281"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1080075941", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-07", 
    "datePublishedReg": "2012-07-01", 
    "description": "PURPOSE: Bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor, is widely used in association with standard chemotherapy in metastatic cancer. Well tolerated, bevacizumab is sometimes associated with serious adverse drug reactions (ADRs). The objective of this study is to describe the profile of ADRs related to bevacizumab and reported to the French Pharmacovigilance system.\nMETHOD: All serious cases of ADRs associated with bevacizumab recorded in the French Pharmacovigilance database up to November 31, 2010 were identified and analyzed, focusing on patient information, drug exposure, and characteristics of the ADRs. Categorical variables were compared using the chi-square test when appropriate.\nRESULTS: A total of 351 serious cases involving 626 ADRs were recorded in the database during the study interval. The most frequent ADRs reported involved the gastrointestinal system (21.9%). The most frequent ADRs included gastrointestinal perforation (4.8%), thromboembolic events (4.0%), pulmonary embolism (3.2%), hypertension (2.7%), gastrointestinal hemorrhage (2.7%), and cerebral hemorrhage or vascular accident (2.6%). The median duration of bevacizumab exposure was four cycles (range 1-30) when ADRs occurred. In 18 cases of death directly caused by ADRs, 50% occurred after only one cycle. In cases of disability, 40% of ADRs were neurologic: neuropathy, paralysis, and paresis.\nCONCLUSION: To the best of our knowledge, this is the first analysis of bevacizumab safety profile using data collected in a national pharmacovigilance database. Our study confirms the frequency and seriousness of gastrointestinal, thromboembolic, and hemorrhage events with bevacizumab use and provides a picture of the bevacizumab safety profile in daily medical practice, despite intrinsic limitations.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00228-012-1232-7", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1054337", 
        "issn": [
          "0031-6970", 
          "1432-1041"
        ], 
        "name": "European Journal of Clinical Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "7", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "68"
      }
    ], 
    "name": "Bevacizumab-induced serious side-effects: a review of the French pharmacovigilance database", 
    "pagination": "1103-1107", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "147d0de3b4fd5e5bfe45bb492efd6b79f0b531698a7488accf217d2cf35dde2d"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22349162"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "1256165"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00228-012-1232-7"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1004299839"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00228-012-1232-7", 
      "https://app.dimensions.ai/details/publication/pub.1004299839"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T20:46", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8684_00000510.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs00228-012-1232-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00228-012-1232-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00228-012-1232-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00228-012-1232-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00228-012-1232-7'


 

This table displays all metadata directly associated to this object as RDF triples.

196 TRIPLES      21 PREDICATES      57 URIs      40 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00228-012-1232-7 schema:about N002157bedb634def8f129532d560f559
2 N21fe34e85e5f4964af6e97fa8e087235
3 N396c8751eff641ec93d005324df3d9d9
4 N3b1f794684974f35b67824cae0157f4f
5 N3cf55e75ae9e4816970491ec8d4e06c8
6 N418bd0ad6152436885faf5be262ef975
7 N53fa700a6a134608a3b7d4d9244ac800
8 N553bda410bd040c5816b44da14747a45
9 N6d4fe3edd8a940778f28fceb04135b44
10 N77ab97ab5e2a40b9a43cade63b15352c
11 N797087ad99e6443ca0e88530e63f1409
12 N7db42e6abc5a47718579a6851c89b967
13 N82f4d67659594663927e4a67f985a62d
14 N8739fb4cdb4c4d2c875d5b16eb17f5a7
15 N9e83008985904e5d8871e02be9d7fe53
16 Na952299b24fa4b0995bde876fe98c2e1
17 Nc562d5ec9cdb480f836e75390f64e55a
18 Nce0573aae5aa4b159dd5de1baf137e7c
19 Nd8951ca5eb5348c494997f0da9dca373
20 anzsrc-for:11
21 anzsrc-for:1117
22 schema:author N54773d8a5a29441f90035dda8305cedc
23 schema:citation sg:pub.10.1038/sj.bjc.6603813
24 https://app.dimensions.ai/details/publication/pub.1080075941
25 https://doi.org/10.1001/jama.2008.656
26 https://doi.org/10.1001/jama.288.13.1588
27 https://doi.org/10.1016/j.clinthera.2006.11.015
28 https://doi.org/10.1016/s0049-3848(10)70014-1
29 https://doi.org/10.1016/s0140-6736(00)02799-9
30 https://doi.org/10.1016/s1359-6349(08)70290-8
31 https://doi.org/10.1016/s1470-2045(09)70112-3
32 schema:datePublished 2012-07
33 schema:datePublishedReg 2012-07-01
34 schema:description PURPOSE: Bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor, is widely used in association with standard chemotherapy in metastatic cancer. Well tolerated, bevacizumab is sometimes associated with serious adverse drug reactions (ADRs). The objective of this study is to describe the profile of ADRs related to bevacizumab and reported to the French Pharmacovigilance system. METHOD: All serious cases of ADRs associated with bevacizumab recorded in the French Pharmacovigilance database up to November 31, 2010 were identified and analyzed, focusing on patient information, drug exposure, and characteristics of the ADRs. Categorical variables were compared using the chi-square test when appropriate. RESULTS: A total of 351 serious cases involving 626 ADRs were recorded in the database during the study interval. The most frequent ADRs reported involved the gastrointestinal system (21.9%). The most frequent ADRs included gastrointestinal perforation (4.8%), thromboembolic events (4.0%), pulmonary embolism (3.2%), hypertension (2.7%), gastrointestinal hemorrhage (2.7%), and cerebral hemorrhage or vascular accident (2.6%). The median duration of bevacizumab exposure was four cycles (range 1-30) when ADRs occurred. In 18 cases of death directly caused by ADRs, 50% occurred after only one cycle. In cases of disability, 40% of ADRs were neurologic: neuropathy, paralysis, and paresis. CONCLUSION: To the best of our knowledge, this is the first analysis of bevacizumab safety profile using data collected in a national pharmacovigilance database. Our study confirms the frequency and seriousness of gastrointestinal, thromboembolic, and hemorrhage events with bevacizumab use and provides a picture of the bevacizumab safety profile in daily medical practice, despite intrinsic limitations.
35 schema:genre research_article
36 schema:inLanguage en
37 schema:isAccessibleForFree false
38 schema:isPartOf N975ba567bd03472da0f9a90ad96f9e31
39 Nc103624e8e0f4e2e9f3e4a556a50f3ac
40 sg:journal.1054337
41 schema:name Bevacizumab-induced serious side-effects: a review of the French pharmacovigilance database
42 schema:pagination 1103-1107
43 schema:productId N05baf2137047441dad45569eb715fccb
44 N7192ee3c91dc4f068968c3e7eeae3d37
45 N876a91b7bf47479a8a7bd50dd279b47b
46 Nb8fed26426744d82af41ee730559c922
47 Ned6db34f24914fe79d8d73359e5bd32d
48 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004299839
49 https://doi.org/10.1007/s00228-012-1232-7
50 schema:sdDatePublished 2019-04-10T20:46
51 schema:sdLicense https://scigraph.springernature.com/explorer/license/
52 schema:sdPublisher Nf29ff5d28729443c9fe541cb8a77b7f7
53 schema:url http://link.springer.com/10.1007%2Fs00228-012-1232-7
54 sgo:license sg:explorer/license/
55 sgo:sdDataset articles
56 rdf:type schema:ScholarlyArticle
57 N002157bedb634def8f129532d560f559 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
58 schema:name Bevacizumab
59 rdf:type schema:DefinedTerm
60 N05baf2137047441dad45569eb715fccb schema:name readcube_id
61 schema:value 147d0de3b4fd5e5bfe45bb492efd6b79f0b531698a7488accf217d2cf35dde2d
62 rdf:type schema:PropertyValue
63 N100ed8709bb74ce59b4d4c84659fce38 rdf:first N7495194ca0d040dabcbf79d286acfae4
64 rdf:rest rdf:nil
65 N21fe34e85e5f4964af6e97fa8e087235 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
66 schema:name Child
67 rdf:type schema:DefinedTerm
68 N396c8751eff641ec93d005324df3d9d9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Male
70 rdf:type schema:DefinedTerm
71 N3b1f794684974f35b67824cae0157f4f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Angiogenesis Inhibitors
73 rdf:type schema:DefinedTerm
74 N3cf55e75ae9e4816970491ec8d4e06c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Adult
76 rdf:type schema:DefinedTerm
77 N418bd0ad6152436885faf5be262ef975 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Adolescent
79 rdf:type schema:DefinedTerm
80 N50eb92b99a5046d7bfa4011b9828a16f rdf:first sg:person.01251754413.49
81 rdf:rest Na21c9f51dabd4bbd8b38e5ea94173996
82 N53fa700a6a134608a3b7d4d9244ac800 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Drug-Related Side Effects and Adverse Reactions
84 rdf:type schema:DefinedTerm
85 N54773d8a5a29441f90035dda8305cedc rdf:first Nb7a56d38881941e28d76bae1b17e26b4
86 rdf:rest N50eb92b99a5046d7bfa4011b9828a16f
87 N553bda410bd040c5816b44da14747a45 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Child, Preschool
89 rdf:type schema:DefinedTerm
90 N6d4fe3edd8a940778f28fceb04135b44 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Pharmacovigilance
92 rdf:type schema:DefinedTerm
93 N7192ee3c91dc4f068968c3e7eeae3d37 schema:name pubmed_id
94 schema:value 22349162
95 rdf:type schema:PropertyValue
96 N7495194ca0d040dabcbf79d286acfae4 schema:familyName the French Network of the Pharmacovigilance Centers
97 rdf:type schema:Person
98 N77ab97ab5e2a40b9a43cade63b15352c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Aged
100 rdf:type schema:DefinedTerm
101 N797087ad99e6443ca0e88530e63f1409 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Antibodies, Monoclonal, Humanized
103 rdf:type schema:DefinedTerm
104 N7db42e6abc5a47718579a6851c89b967 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Female
106 rdf:type schema:DefinedTerm
107 N82f4d67659594663927e4a67f985a62d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Databases, Factual
109 rdf:type schema:DefinedTerm
110 N8739fb4cdb4c4d2c875d5b16eb17f5a7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Adverse Drug Reaction Reporting Systems
112 rdf:type schema:DefinedTerm
113 N876a91b7bf47479a8a7bd50dd279b47b schema:name nlm_unique_id
114 schema:value 1256165
115 rdf:type schema:PropertyValue
116 N975ba567bd03472da0f9a90ad96f9e31 schema:volumeNumber 68
117 rdf:type schema:PublicationVolume
118 N9e83008985904e5d8871e02be9d7fe53 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Middle Aged
120 rdf:type schema:DefinedTerm
121 Na21c9f51dabd4bbd8b38e5ea94173996 rdf:first sg:person.01244544521.38
122 rdf:rest Nd7c12e28276745fdb0d69a6bd34ab7e6
123 Na952299b24fa4b0995bde876fe98c2e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name France
125 rdf:type schema:DefinedTerm
126 Nb7a56d38881941e28d76bae1b17e26b4 schema:affiliation https://www.grid.ac/institutes/grid.414441.0
127 schema:familyName Taugourdeau-Raymond
128 schema:givenName Solène
129 rdf:type schema:Person
130 Nb8fed26426744d82af41ee730559c922 schema:name dimensions_id
131 schema:value pub.1004299839
132 rdf:type schema:PropertyValue
133 Nc103624e8e0f4e2e9f3e4a556a50f3ac schema:issueNumber 7
134 rdf:type schema:PublicationIssue
135 Nc562d5ec9cdb480f836e75390f64e55a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Humans
137 rdf:type schema:DefinedTerm
138 Nce0573aae5aa4b159dd5de1baf137e7c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Young Adult
140 rdf:type schema:DefinedTerm
141 Nd7c12e28276745fdb0d69a6bd34ab7e6 rdf:first sg:person.01312657721.32
142 rdf:rest N100ed8709bb74ce59b4d4c84659fce38
143 Nd8951ca5eb5348c494997f0da9dca373 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Aged, 80 and over
145 rdf:type schema:DefinedTerm
146 Ned6db34f24914fe79d8d73359e5bd32d schema:name doi
147 schema:value 10.1007/s00228-012-1232-7
148 rdf:type schema:PropertyValue
149 Nf29ff5d28729443c9fe541cb8a77b7f7 schema:name Springer Nature - SN SciGraph project
150 rdf:type schema:Organization
151 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
152 schema:name Medical and Health Sciences
153 rdf:type schema:DefinedTerm
154 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
155 schema:name Public Health and Health Services
156 rdf:type schema:DefinedTerm
157 sg:journal.1054337 schema:issn 0031-6970
158 1432-1041
159 schema:name European Journal of Clinical Pharmacology
160 rdf:type schema:Periodical
161 sg:person.01244544521.38 schema:affiliation https://www.grid.ac/institutes/grid.414441.0
162 schema:familyName Default
163 schema:givenName A.
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01244544521.38
165 rdf:type schema:Person
166 sg:person.01251754413.49 schema:affiliation https://www.grid.ac/institutes/grid.414441.0
167 schema:familyName Rouby
168 schema:givenName F.
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01251754413.49
170 rdf:type schema:Person
171 sg:person.01312657721.32 schema:affiliation https://www.grid.ac/institutes/grid.414441.0
172 schema:familyName Jean-Pastor
173 schema:givenName M.-J.
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01312657721.32
175 rdf:type schema:Person
176 sg:pub.10.1038/sj.bjc.6603813 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051627506
177 https://doi.org/10.1038/sj.bjc.6603813
178 rdf:type schema:CreativeWork
179 https://app.dimensions.ai/details/publication/pub.1080075941 schema:CreativeWork
180 https://doi.org/10.1001/jama.2008.656 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048505634
181 rdf:type schema:CreativeWork
182 https://doi.org/10.1001/jama.288.13.1588 schema:sameAs https://app.dimensions.ai/details/publication/pub.1054166281
183 rdf:type schema:CreativeWork
184 https://doi.org/10.1016/j.clinthera.2006.11.015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015591784
185 rdf:type schema:CreativeWork
186 https://doi.org/10.1016/s0049-3848(10)70014-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053698315
187 rdf:type schema:CreativeWork
188 https://doi.org/10.1016/s0140-6736(00)02799-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026617336
189 rdf:type schema:CreativeWork
190 https://doi.org/10.1016/s1359-6349(08)70290-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020222895
191 rdf:type schema:CreativeWork
192 https://doi.org/10.1016/s1470-2045(09)70112-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024981528
193 rdf:type schema:CreativeWork
194 https://www.grid.ac/institutes/grid.414441.0 schema:alternateName Hôpital Salvator
195 schema:name Hôpital Salvator, Assistance Publique des Hôpitaux de Marseille (AP-HM), Centre Régional de Pharmacovigilance, 249 Boulevard Sainte Marguerite, 13009, Marseille, France
196 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...